ANX Mast Therapeutics, Inc.

MicroStockProfit.com announces an investment report featuring ADVENTRX Pharmaceuticals Inc. (Amex:ANX).  The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/ANX

ADVENTRX Pharmaceuticals Inc. (ANX) is a development-stage biopharmaceutical company.  The Company's business is focused on in-licensing, developing and commercializing product candidates for the treatment of cancer.  Its lead product candidates, ANX-530 and ANX-514, are emulsion formulations of marketed chemotherapy drugs.  ANX is focused primarily on evaluating strategic options, including the sale or exclusive license of one or more of its product candidate programs, a strategic business merger and other similar transactions.  In October 2008, ANX announced that it had discontinued active work on all product candidates other than ANX-530 and ANX-514.  Its wholly owned subsidiaries include SD Pharmaceuticals Inc. (SDP) and ANX (Europe) Ltd. 

Message Board Search for ANX: http://www.boardcentral.com/boards/ANX

In the report, the analyst notes:

"ANX's net loss applicable to common stock for the first quarter of 2010 was $4.9 million, or $0.48 per share, compared to a net loss applicable to common stock of $3.2 million, or $0.87 per share, for the same period in 2009.  Included in the net loss applicable to common stock for the first quarter of 2010 was a non-cash, deemed dividend expense of $2.5 million incurred in connection with the Company's January 2010 equity financing.  

"ANX recently announced that it has completed the previously announced sale of shares of its Series F convertible preferred stock pursuant to a registered direct offering to institutional investors, representing gross proceeds to ANX of approximately $19.2 million.  ANX plans to use the net proceeds from the offering to fund activities relating to acquiring and developing additional product candidates, to continue development of its current lead product candidates, and for general corporate purposes."

To read the entire report visit: www.microstockprofit.com/ads/ANX

See what investors are saying about ANX at penny stock forum

MicroStockProfit.com is a small-cap research and investment commentary provider.  MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor.  We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them.  For more information on MicroStockProfit please visit: http://www.microstockprofit.com.

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities.  MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication.  Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT:  MicroStockProfit.com
          Brian Johnson
          1-888-307-2850
          info@microstockprofit.com